XML 24 R14.htm IDEA: XBRL DOCUMENT v3.20.2
SUPPLEMENTAL BALANCE SHEET INFORMATION
 6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION SUPPLEMENTAL BALANCE SHEET INFORMATION
Inventory consisted of the following:
June 30,
2020		December 31,
2019
Raw materials$81,132  $74,442  
Work-in-process370,148  349,978  
Finished goods292,572  255,855  
Total inventory$743,852  $680,275  
Inventory as of June 30, 2020, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling $72.4 million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. The Company believes that all material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale have been significantly reduced. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If regulatory approval is not obtained, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed to Research and Development (R&D).
Accounts Payable and Accrued Liabilities consisted of the following:
June 30,
2020		December 31,
2019
Accounts payable and accrued operating expenses$205,870  $240,981  
Accrued compensation expense115,120  192,467  
Accrued rebates payable63,542  57,163  
Accrued royalties payable20,687  30,797  
Lease liabilities11,387  10,700  
Value added taxes payable7,594  8,395  
Forward foreign currency exchange contracts7,435  10,448  
Deferred revenue5,350  13,037  
Other6,217  6,633  
Total accounts payable and accrued liabilities$443,202  $570,621